PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3182278

Beta-gamma point source on the skin problem--activity estimation and dose analysis.

G E Chabot·K W Skrable
View original source ↗Export metadata ↓

Abstract

This paper presents the analytical approaches used and results obtained by the authors in the evaluation of the dose significance of maintaining a microscopic particle of beta-gamma emitting radionuclides on the skin for a finite time interval. The correlation of the response of a portable measuring instrument with radioactivity content of the particle is discussed along with the subsequent evaluation of dose to a limited skin area. Examples are given to show how two independent theoretical approaches were used to estimate the activity of 60Co from a single poor geometry measurement made with a thin window ionization chamber and how the results compared with empirical results from laboratory measurements on a prepared 60Co source. The application of Loevinger's point beta source dose distribution function and other dosimetric information is presented. A summary table and simplified equations to predict beta dose rates to 1 cm2 of tissue at a depth of 7 mg cm-2 for 3.7 X 10(4) Bq point isotropic sources of hypothetical beta emitters ranging in end point energies from 0.2 to 3 MeV and in atomic number from 10 to 90 are also included.

Explore related subjects

Beta ParticlesCobalt RadioisotopesGamma RaysHumansRadiation DosageRadiometrySkinJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G E Chabot, K W Skrable. 1988. Beta-gamma point source on the skin problem--activity estimation and dose analysis.. https://doi.org/10.1097/00004032-198811000-00002

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Beta radiation exposure of medical staff and implications for extremity dose monitoring.

Sealed and unsealed beta radiation sources come into use to a greater extent in radiation therapy, e.g. for treating inflammatory joint diseases by radiosynoviorthesis (RSO), by injecting 90Y, 186Re or 169Er-solutions. Sealed 90Sr/90Y and 32P-sources or 188Re-liquid-filled balloon catheter are applied in vascular brachytherapy. Recently, 90Y-labelled antibodies are being successfully used in radioimmunotherapy (RIT) of malign lymphoma. Such practices require handling of high activities at small distances to the skin. Thus, the medical staff may be exposed to high beta doses. Investigations of the extremity exposure were performed at several workplaces, in particular during RSO treatments. The local skin dose (LSD), Hp(0,07), was measured with thin-layer TLD (LiF:Mg,P,Cu) fixed to the fingers (TLD-tapes). The findings indicate that the exposure of the staff can exceed the annual dose limit of 500 mSv when working at low protection standard. Routine monitoring of the extremity exposures with ring dosemeters appropriate to beta radiation and provided by the approved German dosimetry services was found to be needed. But even monitoring with these official 'beta-dosemeters' does mostly not give suitable results to demonstrate compliance with the dose limit. A study was conducted at RSO-workplaces in order reveal a correlation between doses measured with ring dosemeters and the maximum LSD obtained from the TLD-tapes. The results are discussed and conclusions for routine monitoring are drawn.

Beta Particles↗
PubMed2007

Beta radiation shielding with lead and plastic: effect on bremsstrahlung radiation when switching the shielding order.

Lead and plastic are commonly used to shield beta radiation. Radiation protection literature is ubiquitous in advising the placement of plastic first to absorb all the beta particles before any lead shielding is used. This advice is based on the well established theory that radiative losses (bremsstrahlung production) are more prevalent in higher atomic number (Z) materials than in low Z materials. Using 32P beta radiation, we measured bremsstrahlung photons transmitted through lead and plastic (Lucite) shielding in different test configurations to determine the relative efficacy of lead alone, plastic alone, and the positional order of lead and plastic. With the source (32P) and detector held at a constant separation distance, we inserted lead and/or plastic absorbers and measured the reduction in bremsstrahlung radiation level measured by the detector. With these test conditions, analysis of measured bremsstrahlung radiation in various thicknesses and configurations of lead and plastic shielding shows the following: placing plastic first vs. lead first reduces the transmitted radiation level only marginally (10% to 40%); 2 mm of additional lead is sufficient to correct the "mistake" of placing the lead first; and for equal thicknesses or weights of lead and plastic, lead is a more efficient radiation shield than plastic.

Beta Particles↗
PubMed2006

A meta-analysis of randomized controlled trials of intracoronary gamma- and beta-radiation therapy for in-stent restenosis.

We assessed the effectiveness of intracoronary brachytherapy and compared treatment effects for the two radiation sources as well as the performance of the procedure in saphenous vein grafts (SVG) and native coronary arteries. Five randomized controlled trials comparing intracoronary brachytherapy with placebo involving a total of 1310 patients were reviewed for a meta-analysis. Risk differences (RD) for major adverse cardiac events (MACE), target vessel revascularization, target lesion revascularization, and angiographic binary restenosis at 6-12 months were computed, and a meta-regression analysis of MACE was performed. For MACE, the RD was 0.19 (95% confidence interval [CI], 0.09%-0.29%; P value, 0.00); there was significant between-study variance of 0.2395. In univariate meta-regression analyses, diabetes was a significant factor for the between-study variance (P value, 0.000). In multivariate meta-regression analyses adjusted for diabetes and lesion length, neither gamma-radiation source nor SVG was a significant factor for the between-study variance (P value, 0.675 and 0.433, respectively); the adjusted between-study variance was 0.000. Intra-coronary brachytherapy is effective compared with placebo at mid-term follow up. Neither procedure in SVG (gamma radiation) nor difference in radiation source (beta or gamma) in native coronary arteries was a significant factor in brachytherapy effectiveness compared to placebo.

Beta Particles↗